BNT162b2 Against COVID-19-Associated Emergency Department and Urgent Care Visits Among Children 5-11 Years of Age: A Test Negative Design

被引：3

作者：

Tartof, Sara Y. ^{[1
,2
]}

Frankland, Timothy B. ^{[3
]}

Puzniak, Laura ^{[4
]}

Slezak, Jeff M. ^{[1
]}

Hong, Vennis ^{[1
]}

Takhar, Harpreet ^{[1
]}

Ogun, Oluwaseye A. ^{[1
]}

Simmons, Sarah ^{[1
]}

Xie, Fagen ^{[1
]}

Zamparo, Joann ^{[4
]}

Ackerson, Bradley K. ^{[5
]}

Jodar, Luis ^{[4
]}

McLaughlin, John M. ^{[4
]}

机构：

[1] Kaiser Permanente Southern Calif, Dept Res & Evaluat, 1000 S Los Robles,2nd Floor, Pasadena, CA 91101 USA

[2] Kaiser Permanente Bernard J Tyson Sch Med, Dept Hlth Syst Sci, Pasadena, CA USA

[3] Kaiser Permanente Hawaii Ctr Integrated Hlth Care, Honolulu, HI USA

[4] Pfizer Inc, Collegeville, PA USA

[5] Southern Calif Permanente Med Grp, Harbor City, CA USA

来源：

JOURNAL OF THE PEDIATRIC INFECTIOUS DISEASES SOCIETY | 2023年 / 12卷 / 03期

关键词：

BNT162b2; booster; COVID-19; delta; effectiveness; Kaiser Permanente; omicron; pediatric; real-world; SARS-CoV-2; test-negative; United States; VACCINE;

D O I：

10.1093/jpids/piad005

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

In a 1:1 matched test-negative design among 5- to 11-year-olds in the Kaiser Permanente Southern California health system (n = 3984), BNT162b2 effectiveness against the omicron-related emergency department or urgent care encounters was 60% [95%CI: 47-69] <3 months post-dose-two and 28% [8-43] after >= 3 months. A booster improved protection to 77% [53-88].

引用

页码：177 / 179

页数：3

共 50 条

[31] In subjects 16 years of age and older, is messenger RNA vaccine BNT162b2 against COVID-19 effective and safe?
Lanthier, L.
Carignan, A.
Plourde, M-E.
Cauchon, M.
REVUE DE MEDECINE INTERNE, 2021, 42 (03): : 227 - 228
[32] Effectiveness of BNT162b2 vaccine against symptomatic SARS-CoV-2 infection in children aged 5-11 years in Japan during Omicron variant predominate periods
Hara, Megumi
Ohta, Yuko
Fusazaki, Naoki
Hirota, Yoshio
JOURNAL OF EPIDEMIOLOGY, 2024, 34 (05) : 205 - 210
[33] Short term safety of BNT162b2 (Pfizer-BioNTech) SARS-CoV-2 vaccine among children aged 5-11 years, a nationwide parental survey
Ben David, Shirley Shapiro
Gez, Sharon Baruch
Adler, Limor
Kovatch, Rada
Rahamim-Cohen, Daniella
Shamir-Stein, Na'ama
Shahar, Arnon
Mizrhi-Reuveni, Miri
VACCINE, 2024, 42 (05) : 1154 - 1159
[34] PaedVacCOVID - safety of the BNT162b2 vaccine against the SARS-CoV-2 in children with and without comorbidities aged 5 to 11 years
Holzwarth, Sarah
Saadat, Kimiya
Jorczyk, Maximilian
Dressen, Svenja
Kotsias-Konopelska, Sarah
Schlegtendal, Anne
Maier, Christoph
Schmitt, Jochen
Paul, Kevin
Pagel, Julia
Muntau, Ania C.
Berner, Reinhard
Brinkmann, Folke
Toepfner, Nicole
INFECTION, 2024, : 615 - 624
[35] Safety and antibody response of the BNT162b2 SARS-CoV-2 vaccine in children aged 5-11 years with underlying diseases: A prospective observational study
Funaki, Takanori
Yamada, Masaki
Miyake, Kozue
Ueno, Saki
Myojin, Shota
Aiba, Hiroyuki
Matsui, Toshihiro
Ogimi, Chikara
Kato, Hitoshi
Miyairi, Isao
Shoji, Kensuke
JOURNAL OF INFECTION AND CHEMOTHERAPY, 2024, 30 (08) : 773 - 779
[36] Effectiveness of BNT162b2 and mRNA-1273 Vaccines against COVID-19 Infection: A Meta-Analysis of Test-Negative Design Studies
Chang, Shuailei
Liu, Hongbo
Wu, Jian
Xiao, Wenwei
Chen, Sijia
Qiu, Shaofu
Duan, Guangcai
Song, Hongbin
Zhang, Rongguang
VACCINES, 2022, 10 (03)
[37] Effectiveness of BNT162b2 and CoronaVac against COVID-19-related severe outcomes among children and adolescents: A Brazilian nationwide cohort study
de Lima, Eliandra da Silveira
Antunes, Marcos Otavio Brum
de Souza, Jesuely Spieckert
Jones, Marcus H.
Stein, Renato T.
Pinto, Leonardo A.
Friedrich, Frederico
Scotta, Marcelo Comerlato
VACCINE, 2025, 44
[38] Safety monitoring of BNT162b2 (Pfizer-BioNTech) COVID-19 vaccines in US children aged 5-17 years
Hu, Mao
Wong, Hui-Lee
Feng, Yuhui
Lloyd, Patricia C.
Smith, Elizabeth R.
Amend, Kandace L.
Beachler, Daniel C.
Gruber, Joann F.
Mitra, Mahasweta
Seeger, John D.
Secora, Alex
Obidi, Joyce
Wang, Jing
Song, Jennifer
McMahill-Walraven, Cheryl N.
Djibo, Djeneba Audrey
McEvoy, Rowan
Do, Rose
Chillarige, Yoganand
Clifford, Robin
Shoaibi, Azadeh
Forshee, Richard A.
Anderson, Steven A.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2023, 32 : 109 - 110
[39] BNT162b2 mRNA COVID-19 against symptomatic Omicron infection following a mass vaccination campaign in southern Brazil: A prospective test-negative design study
Rosa, Regis Goulart
Falavigna, Maicon
Manfio, Joselia Larger
de Araujo, Cintia Laura Pereira
Cohen, Mirian
Barbosa, Gynara Rezende Gonzalez do Valle
de Souza, Ana Paula
Silva, Fernanda Kelly Romeiro
Sganzerla, Daniel
da Silva, Mariana Motta Dias
Ferreira, Diogo
Rodrigues, Cristina de Oliveira
de Souza, Emanuel Maltempi
de Oliveira, Jaqueline Carvalho
Gradia, Daniela Fiori
Brandalize, Ana Paula Carneiro
Royer, Carla Adriane
Luiz, Rafael Messias
Kucharski, Gabriela Almeida
Pedrotti, Fernando
Valluri, Srinivas Rao
Srivastava, Amit
Juliao, Viviane Wal
Melone, Olga Chameh
Allen, Kristen E.
Kyaw, Moe H.
Spinardi, Julia
Castillo, Graciela del Carmen Morales
McLaughlin, John M.
VACCINE, 2023, 41 (37) : 5461 - 5468
[40] Effectiveness of BNT162b2 COVID-19 primary series vaccination in children aged 5-17 years in the United States: a cohort study
Ogilvie, Rachel P.
Layton, J. Bradley
Lloyd, Patricia C.
Jiao, Yixin
Djibo, Djeneba Audrey
Wong, Hui Lee
Gruber, Joann F.
Parambi, Ron
Deng, Jie
Miller, Michael
Song, Jennifer
Weatherby, Lisa B.
Peetluk, Lauren
Lo, An-Chi
Matuska, Kathryn
Wernecke, Michael
Bui, Christine L.
Clarke, Tainya C.
Cho, Sylvia
Bell, Elizabeth J.
Yang, Grace
Amend, Kandace L.
Forshee, Richard A.
Anderson, Steven A.
McMahill-Walraven, Cheryl N.
Chillarige, Yoganand
Anthony, Mary S.
Seeger, John D.
Shoaibi, Azadeh
BMC PEDIATRICS, 2024, 24 (01)

← 1 2 3 4 5 →